Given the amount of shares out there, my guess is that IND approved status gets us to .08~.10. It might initially spike up higher, to maybe .15, but people will take profits at that point and it'll drop back for awhile.
Longer term, as the trials go on and/or they introduce new variants or other stem-cell based therapies, I could see it getting up to .25~.40. If that happens, I suspect a reverse split will happen that will push us up to ~$5 and a re-listing on the NASDAQ. From there, who knows?
I think BMSN is a good call short term, medium term, and long term. It really doesn't seem like the normal penny stock pump-n-dumps to me.
